1. Home
  2. Products
  3. Waylivra▼ (volanesorsen)
  4. Mode of Action
Waylivra - About FCS

Waylivra mode of action

 
Waylivra is an antisense oligonucleotide designed to inhibit the formation of ApoC-III.1
 

By reducing ApoC-III, Waylivra removes an inhibitor of triglyceride clearance, enabling triglyceride metabolism through an LPL-independent pathway in patients with FCS.1

 

Waylivra MOA video

lightening    Limited functionality. 

ApoC-III: apolipoprotein C-III, FCS: familial chylomicronemia syndrome, LPL: lipoprotein lipase, TG: triglycerides, TRL: triglyceride-rich lipoprotein, VLDL: very low-density lipoprotein
Adapted from Gaudet D et al. N Engl J Med 2014;371(23):2200–6 and Crooke RM. Expert Opin Biol Ther 2005;5(7):907–17.

 

References

  1. Waylivra Summary of Product Characteristics. London. 
  2. Witzum JL et al. N Engl J Med 2019;381(6):531–42.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.  Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754

PP-22579
Other sites
expand_less